{"filings":[{"id":1204917,"accession_number":"0001193125-26-278581","cik":1882782,"company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","form_type":"8-K","filed_at":"2026-06-23T12:45:40+00:00","items":["7.01","9.01"],"status":"ready","headline":"Odyssey Therapeutics posts June 2026 corporate presentation on website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1; no specific financial or clinical updates provided in filing text.","No detailed content available; summary based solely on filing metadata.","Ticker ODTX; presentation posted on investors.odysseytx.com.","Event reported under Regulation FD; no earnings or material agreements disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":839704694.2156,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1112597,"accession_number":"0001193125-26-274291","cik":1882782,"company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","form_type":"8-K","filed_at":"2026-06-17T20:45:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Odyssey Therapeutics Q1 net loss $38.3M; pro-forma cash $464M; positive OD-001 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and securities $175.7M at Mar 31, 2026; pro-forma cash $464.4M after IPO net proceeds of $288.7M.","Net loss of $38.3M for Q1 2026, comparable to $38.4M in Q1 2025.","R&D expenses $32.3M (down $6.5M YoY); G&A $7.4M (down $0.6M YoY).","Phase 2a proof-of-concept for OD-001: 27% clinical remission, 61% clinical response in UC.","Plan to launch Phase 2b monotherapy and Phase 2a combo trial with vedolizumab in H2 2026; data H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":839704694.2156,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13883,"accession_number":"0001193125-26-216899","cik":1882782,"company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","form_type":"8-K","filed_at":"2026-05-11T20:30:18+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Odyssey Therapeutics raises $25M from TPG affiliate in private placement concurrent with IPO at $18/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 1,388,889 shares of common stock at $18.00 per share for total proceeds of $25,000,002.","Placement closed concurrently with the IPO on May 11, 2026; shares are registrable under existing Investor Rights Agreement.","J.P. Morgan, TD Securities, Cantor Fitzgerald, Wedbush, Oppenheimer acted as placement agents; fee of 7% of purchase price.","Company filed amended certificate of incorporation and bylaws effective upon IPO closing on May 11, 2026.","TPG LSI Rise Orazio II, L.P., an affiliate of an existing stockholder, is the purchaser."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":839704694.2156,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}